Abstract
In prostate cancer, men diagnosed with low risk disease may be monitored through an active surveillance. This research explored the perspectives of men with prostate cancer regarding their decision-making process for active surveillance to identify factors that influence their decision and assist health professionals in having conversations about this option. Focus group interviews (n = 7) were held in several Canadian cities with men (N = 52) diagnosed with prostate cancer and eligible for active surveillance. The men's viewpoints were captured regarding their understanding of active surveillance, the factors that influenced their decision, and their experience with the approach. A content and theme analysis was performed on the verbatim transcripts from the sessions. Patients described their concerns of living with their disease without intervention, but were reassured by the close monitoring under AS while avoiding harmful side effects associated with treatments. Conversations with their doctor and how AS was described were cited as key influences in their decision, in addition to availability of information on treatment options, distrust in the health system, personality, experiences and opinions of others, and personal per...Continue Reading
References
Jul 15, 2009·BJU International·Roderick C N van den BerghMarie-Louise Essink-Bot
Oct 21, 2009·CA: a Cancer Journal for Clinicians·Grace A LinR Adams Dudley
Nov 19, 2010·BJU International·Carmel N AnandadasUNKNOWN North West Uro-oncology Group
Apr 22, 2011·BJU International·B Joyce Davison, S Larry Goldenberg
Dec 20, 2011·Patient Education and Counseling·Barbara Joyce Davison, Erin Breckon
Feb 24, 2012·Current Opinion in Urology·Roderick C N van den BerghChris H Bangma
Sep 1, 2012·Current Urology Reports·Alexander P GlaserBrian T Helfand
Jan 17, 2013·European Journal of Cancer Care·B TombalC Schulman
Jul 19, 2013·British Journal of Cancer·E W de Bekker-GrobE W Steyerberg
Sep 17, 2013·PloS One·Mark V MishraTimothy N Showalter
Nov 19, 2013·Psycho-oncology·Robert J VolkPatricia Dolan Mullen
Dec 18, 2013·Urologic Oncology·Heather OromWillie Underwood
May 17, 2014·Psycho-oncology·Clare O'CallaghanPenelope Schofield
May 17, 2014·Cancer Nursing·Carolina ChabreraAdelaida Zabalegui
Aug 21, 2014·Psycho-oncology·Lionne D F VenderbosIda J Korfage
Jan 27, 2015·European Urology·Andrew J SimpkinJenny L Donovan
Feb 15, 2015·The Journal of Urology·Kathryn T DinhPaul L Nguyen
Mar 17, 2015·CA: a Cancer Journal for Clinicians·Philippe D VioletteKari A O Tikkinen
Mar 31, 2015·Acta Clinica Belgica·J DevosN Lumen
Jun 10, 2015·The Journal of Urology·Prajakta AdsulSameer Siddiqui
Jul 17, 2015·JAMA Oncology·Ann C RaldowAnthony V D'Amico
Aug 15, 2015·American Journal of Men's Health·Çağatay DoğanCan Öbek
Aug 19, 2015·The Prostate·Francis TingPhillip D Stricker
Oct 31, 2015·Annual Review of Medicine·Itay A SternbergPeter T Scardino
Dec 26, 2015·Urologic Oncology·Lauren M HurwitzInger L Rosner
Jan 28, 2016·Nature Reviews. Urology·Sophie M BruinsmaUNKNOWN Movember GAP3 consortium
Mar 10, 2016·Nature Reviews. Urology·Jeffrey J TosoianStacy Loeb
Jul 23, 2016·World Journal of Urology·Narhari TimilshinaFred Saad
Citations
Mar 28, 2019·Health Informatics Journal·Isabel B de AngstJohanna Jm Takkenberg
Jun 10, 2018·BMC Health Services Research·Kittie PangAnne-Marie Mes-Masson
Jan 19, 2021·Journal of Patient Experience·Margaret FitchAnne-Marie Mes-Masson
Oct 5, 2021·Psycho-oncology·Maggie CunninghamHelen L Richards
Jan 18, 2022·European Journal of Cancer Care·Jai PrasharElizabeth Murray